We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ImmunoGen Starts Phase I Study on Leukemia Candidate IMGN632
Read MoreHide Full Article
ImmunoGen, Inc. announced that it has initiated a phase I study to evaluate its anti-CD123 antibody-drug conjugates (ADCs), IMGN632, for treating patients with hematological malignancies including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Notably, IMGN632 uses the company’s indolino-benzodiazepine cancer-killing agents known as IGNs.
This is ImmunoGen’s second IGN ADC to move into clinical development, the first being IMGN779, a CD33-targeting ADC, already evaluated in a phase I study for the treatment of AML.
We remind investors that the FDA has completed the safety review of the investigational new drug (IND) application for IMGN632 in October last year, which was filed by the company in mid-September for the aforementioned indications. The IND application was supported by positive data from preclinical studies, which demonstrated IMGN63’s promising activity against AML cells while sparing normal bone marrow cells.
ImmunoGen’s shares have significantly outperformed the industry year to date. The stock has skyrocketed 185.6% compared with the industry’s 8.1% increase during the same time frame.
The phase I study will follow a dose regime of IMGN632 once every three weeks. Thereafter, the selected dose will be evaluated in expansion cohorts in patients with the above mentioned hematologic malignancies.
We remind investors that ImmunoGen had earlier entered into a strategic collaboration and option agreement with Jazz Pharmaceuticals PLC (JAZZ - Free Report) in August for the development and commercialization of IMGN632. The collaboration also includes IMGN779.
Notably, ImmunoGen is focused on developing targeted cancer therapeutics using its proprietary ADC technology. In fact, this innovative technology of the company is also used in Roche's (RHHBY - Free Report) marketed product, Kadcyla, and in three other development-stage candidates in its pipeline.
Additionally, the ADC technology is used in development programs by ImmunoGen's partners Amgen (AMGN - Free Report) , Bayer AG, Biotest, CytomX, Eli Lilly, Novartis, Sanofi and Takeda.
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Image: Bigstock
ImmunoGen Starts Phase I Study on Leukemia Candidate IMGN632
ImmunoGen, Inc. announced that it has initiated a phase I study to evaluate its anti-CD123 antibody-drug conjugates (ADCs), IMGN632, for treating patients with hematological malignancies including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Notably, IMGN632 uses the company’s indolino-benzodiazepine cancer-killing agents known as IGNs.
This is ImmunoGen’s second IGN ADC to move into clinical development, the first being IMGN779, a CD33-targeting ADC, already evaluated in a phase I study for the treatment of AML.
We remind investors that the FDA has completed the safety review of the investigational new drug (IND) application for IMGN632 in October last year, which was filed by the company in mid-September for the aforementioned indications. The IND application was supported by positive data from preclinical studies, which demonstrated IMGN63’s promising activity against AML cells while sparing normal bone marrow cells.
ImmunoGen’s shares have significantly outperformed the industry year to date. The stock has skyrocketed 185.6% compared with the industry’s 8.1% increase during the same time frame.
The phase I study will follow a dose regime of IMGN632 once every three weeks. Thereafter, the selected dose will be evaluated in expansion cohorts in patients with the above mentioned hematologic malignancies.
We remind investors that ImmunoGen had earlier entered into a strategic collaboration and option agreement with Jazz Pharmaceuticals PLC (JAZZ - Free Report) in August for the development and commercialization of IMGN632. The collaboration also includes IMGN779.
Notably, ImmunoGen is focused on developing targeted cancer therapeutics using its proprietary ADC technology. In fact, this innovative technology of the company is also used in Roche's (RHHBY - Free Report) marketed product, Kadcyla, and in three other development-stage candidates in its pipeline.
Additionally, the ADC technology is used in development programs by ImmunoGen's partners Amgen (AMGN - Free Report) , Bayer AG, Biotest, CytomX, Eli Lilly, Novartis, Sanofi and Takeda.
ImmunoGen, Inc. Price
ImmunoGen, Inc. Price | ImmunoGen, Inc. Quote
Zacks Rank
ImmunoGen carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>